Lumida
/NTLA
⌘K
Intellia Therapeutics Inc

Intellia Therapeutics Inc

NTLA
$11.38USD-4.09%-0.48 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$11 – $12

52W RANGE

$8
$28

AI Summary

Stalk
TrimHigh

NTLA remains in a Stage 4 decline with confirmed downtrend and a Bearish Pivot Point signaling structural repair. The medium-term bias is bearish, prohibiting long entries and prioritizing sell-side engagement. Short-term timing is unfavorable due to oversold extension below down-sloping EMAs, so execution should wait for shallow rallies into the 9/21 EMA and 50-day SMA cluster for rejection.

  • Phase 3 LOMVOSI shows 87% attack reduction vs placebo.
  • $630.5M cash balance funds operations into mid-2027.
  • FDA clinical hold on NEXE program disrupts enrollment timelines.
Full analysis →
Insider Trades38 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 2, 2026SellNTLAEdward J Iii DulacEVP, Chief Financial Officer4,677$18.00$1.6B-59.73%+43.08%$84.2K-2.91%10b5-1Sell Now
Jul 1, 2026SellNTLAMichael P DubeVP, Chief Accounting Officer2,641$16.78$1.6B-59.73%+43.08%$44.3K-3.80%Sell Now
Mar 2, 2026SellNTLAEliana ClarkEVP, Chief Technical Officer607$13.78$1.6B-59.73%+43.08%$8.4K-0.58%Sell Now
Mar 2, 2026SellNTLAJames BastaEVP, General Counsel1,211$13.78$1.6B-59.73%+43.08%$16.7K-0.54%Sell Now
Jan 5, 2026SellNTLAMichael P DubeVP, Chief Accounting Officer2,989$9.21$1.6B-59.73%+43.08%$27.5K-5.41%Sell Now
Jan 5, 2026SellNTLAEdward J Iii DulacEVP, Chief Financial Officer6,379$9.21$1.6B-59.73%+43.08%$58.8K-6.01%Sell Now
Jan 5, 2026SellNTLABirgit C SchultesEVP, Chief Scientific Officer8,508$9.21$1.6B-59.73%+43.08%$78.4K-7.95%Sell Now
Jan 5, 2026SellNTLAEliana ClarkEVP, Chief Technical Officer9,515$9.21$1.6B-59.73%+43.08%$87.6K-9.85%Sell Now
Jan 5, 2026SellNTLAJames BastaEVP, General Counsel10,397$9.21$1.6B-59.73%+43.08%$95.8K-9.29%Sell Now
Jan 5, 2026SellNTLADavid LebwohlEVP, Chief Medical Officer11,903$9.21$1.6B-59.73%+43.08%$109.6K-8.94%Sell Now
Jan 5, 2026SellNTLAJohn M LeonardPresident and CEO34,146$9.21$1.6B-59.73%+43.08%$314.5K-3.26%Sell Now
Dec 11, 2025SellNTLAJohn M LeonardPresident and CEO146,662$8.43$1.6B-59.73%+43.08%$1.2M-0.55%10b5-1Sell Now
Oct 1, 2025SellNTLABirgit C SchultesEVP, Chief Scientific Officer31$17.38$1.6B-59.73%+43.08%$538.78-0.03%Sell Now
Oct 1, 2025SellNTLAMichael P DubeVP, Chief Accounting Officer1,871$17.38$1.6B-59.73%+43.08%$32.5K-3.27%Sell Now
Jul 23, 2025SellNTLAEdward J Iii DulacEVP, Chief Financial Officer7,462$14.02$1.6B-59.73%+43.08%$104.6K-6.57%Sell Now
Jul 2, 2025SellNTLAMichael P DubeVP, Chief Accounting Officer2,503$9.95$1.6B-59.73%+43.08%$24.9K-4.20%Sell Now
Jul 1, 2025SellNTLAEliana ClarkEVP, Chief Technical Officer1,022$9.82$1.6B-59.73%+43.08%$10.0K-1.06%Sell Now
Mar 4, 2025SellNTLAEliana ClarkEVP, Chief Technical Officer679$8.99$1.6B-59.73%+43.08%$6.1K-0.48%Sell Now
Mar 4, 2025SellNTLAJames BastaEVP, General Counsel2,572$8.99$1.6B-59.73%+43.08%$23.1K-1.50%Sell Now
Jan 3, 2025SellNTLAMichael P DubeVP, Chief Accounting Officer1,372$12.18$1.6B-59.73%+43.08%$16.7K-2.92%Sell Now
Jan 3, 2025SellNTLADerek HicksEVP, Chief Business Officer6,502$12.18$1.6B-59.73%+43.08%$79.2K-9.80%Sell Now
Jan 3, 2025SellNTLAJames BastaEVP, General Counsel7,074$12.18$1.6B-59.73%+43.08%$86.2K-8.67%Sell Now
Jan 3, 2025SellNTLALaura Sepp-LorenzinoEVP, Chief Scientific Officer8,966$12.18$1.6B-59.73%+43.08%$109.2K-10.38%Sell Now
Jan 3, 2025SellNTLADavid LebwohlEVP, Chief Medical Officer9,557$12.18$1.6B-59.73%+43.08%$116.4K-9.83%Sell Now
Jan 3, 2025SellNTLAJohn M LeonardPresident and CEO26,807$12.18$1.6B-59.73%+43.08%$326.5K-2.77%Sell Now
Jan 2, 2025SellNTLAEliana ClarkEVP, Chief Technical Officer7,978$12.17$1.6B-59.73%+43.08%$97.1K-5.56%Sell Now
Oct 2, 2024SellNTLAMichael P DubeVP, Chief Accounting Officer2,012$19.01$1.6B-59.73%+43.08%$38.2K-4.10%Sell Now
Jul 1, 2024SellNTLAEliana ClarkEVP, Chief Technical Officer405$22.93$1.6B-59.73%+43.08%$9.3K-0.56%Sell Now
Mar 4, 2024SellNTLAEliana ClarkEVP, Chief Technical Officer605$32.99$1.6B-59.73%+43.08%$20.0K-0.52%Sell Now
Mar 4, 2024SellNTLAJames BastaEVP, General Counsel2,297$32.99$1.6B-59.73%+43.08%$75.8K-1.76%Sell Now
Jan 8, 2024SellNTLALaura Sepp-LorenzinoEVP, Chief Scientific Officer2,275$28.87$1.6B-59.73%+43.08%$65.7K-2.51%10b5-1Sell Now
Jan 3, 2024SellNTLAJames BastaEVP, General Counsel3,805$29.46$1.6B-59.73%+43.08%$112.1K-6.88%Sell Now
Jan 3, 2024SellNTLADerek HicksEVP, Chief Business Officer3,877$29.46$1.6B-59.73%+43.08%$114.2K-9.49%Sell Now
Jan 3, 2024SellNTLAEliana ClarkEVP, Chief Technical Officer4,608$29.50$1.6B-59.73%+43.08%$136.0K-5.09%Sell Now
Jan 3, 2024SellNTLAGlenn GoddardEVP, Chief Financial Officer5,365$29.46$1.6B-59.73%+43.08%$158.1K-11.68%Sell Now
Jan 3, 2024SellNTLALaura Sepp-LorenzinoEVP, Chief Scientific Officer5,532$29.46$1.6B-59.73%+43.08%$163.0K-10.69%Sell Now
Jan 3, 2024SellNTLADavid LebwohlEVP, Chief Medical Officer5,843$29.46$1.6B-59.73%+43.08%$172.1K-9.70%Sell Now
Jan 3, 2024SellNTLAJohn M LeonardPresident and CEO19,223$29.46$1.6B-59.73%+43.08%$566.3K-2.22%Sell Now